☰

Gehad M. Subaiea, Ph.D. - Publications

Affiliations: 
2013 Pharmaceutical Sciences University of Rhode Island, Providence, RI, United States 
Area:
Pharmacology, Behavioral Psychology, Neuroscience Biology, Cognitive Psychology
Tree Info Grants Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Bihaqi SW, Alansi B, Masoud AM, Mushtaq F, Subaiea GM, Zawia NH. Influence of Early Life Lead (Pb) exposure on α-Synuclein, GSK-3β and Caspase-3 mediated Tauopathy: Implications on Alzheimer's disease. Current Alzheimer Research. PMID 30068273 DOI: 10.2174/1567205015666180801095925  0.654
2018 Masoud AM, Bihaqi SW, Alansi B, Dash M, Subaiea GM, Renehan WE, Zawia NH. Altered microRNA, mRNA, and Protein Expression of Neurodegeneration-Related Biomarkers and Their Transcriptional and Epigenetic Modifiers in a Human Tau Transgenic Mouse Model in Response to Developmental Lead Exposure. Journal of Alzheimer's Disease : Jad. PMID 29614648 DOI: 10.3233/Jad-170824  0.666
2018 Chang JK, Leso A, Subaiea GM, Lahouel A, Masoud A, Mushtaq F, Deeb R, Eid A, Dash M, Bihaqi SW, Zawia NH. Tolfenamic acid: A modifier of the tau protein and its role in cognition and tauopathy. Current Alzheimer Research. PMID 29357795 DOI: 10.2174/1567205015666180119104036  0.702
2016 Dash M, Eid A, Subaiea G, Chang J, Deeb R, Masoud A, Renehan WE, Adem A, Zawia NH. Developmental exposure to lead (Pb) alters the expression of the Human Tau Gene and its products in a transgenic animal model. Neurotoxicology. PMID 27293183 DOI: 10.1016/J.Neuro.2016.06.001  0.674
2015 Adwan L, Subaiea GM, Basha R, Zawia NH. Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies. Journal of Neurochemistry. 133: 266-72. PMID 25279694 DOI: 10.1111/Jnc.12960  0.734
2015 Subaiea GM, Ahmed AH, Adwan LI, Zawia NH. Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid. Journal of Alzheimer's Disease : Jad. 43: 425-33. PMID 25096618 DOI: 10.3233/Jad-132726  0.687
2014 Ahmed AH, Subaiea GM, Eid A, Li L, Seeram NP, Zawia NH. Pomegranate extract modulates processing of amyloid-β precursor protein in an aged Alzheimer's disease animal model. Current Alzheimer Research. 11: 834-43. PMID 25274111 DOI: 10.2174/1567205011666141001115348  0.712
2014 Adwan L, Subaiea GM, Zawia NH. Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. Neuropharmacology. 79: 596-602. PMID 24462621 DOI: 10.1016/J.Neuropharm.2014.01.009  0.745
2014 Bihaqi SW, Bahmani A, Subaiea GM, Zawia NH. Infantile exposure to lead and late-age cognitive decline: relevance to AD. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 187-95. PMID 23867794 DOI: 10.1016/J.Jalz.2013.02.012  0.685
2013 Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH. Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiology of Aging. 34: 2421-30. PMID 23639209 DOI: 10.1016/J.Neurobiolaging.2013.04.002  0.729
2011 Subaiea GM, Alansi BH, Serra DA, Alwan M, Zawia NH. The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms. Current Alzheimer Research. 8: 860-7. PMID 21605061 DOI: 10.2174/156720511798192691  0.664
2011 Adwan LI, Basha R, Abdelrahim M, Subaiea GM, Zawia NH. Tolfenamic acid interrupts the de novo synthesis of the β-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway. Current Alzheimer Research. 8: 385-92. PMID 21557719 DOI: 10.2174/156720511795745285  0.726
Show low-probability matches.